Given the rising global cancer burden and fragmented evidence on digital health interventions (DHIs), this umbrella review synthesizes evidence on DHIs across the cancer control continuum to inform evidence-based practice. We systematically searched PubMed, Medline (via Ovid), Web of Science, Embase, the Cochrane Library, CINAHL, and PsychINFO from database inception to November 7, 2025. Methodological quality of included reviews was assessed using A MeaSurement Tool to Assess systematic Reviews (AMSTAR), and the certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. This umbrella review was registered with PROSPERO (CRD420251236883). Overall, 115 effects from 27 systematic reviews with meta-analyses were included, evaluating the impact of DHIs on cancer screening, psycho-emotional well-being and quality of life, physical symptoms and functioning, cognition, decision-making, and behavior outcomes across the cancer control continuum (prevention and screening, symptom management, emotional and social support, and survivorship). Of these, 62 (53.91%) were statistically significant ( P < 0.05) based on the random-effects model. According to the AMSTAR tool, 14 (51.85%) of the included systematic reviews with meta-analyses were rated as high quality, and none were classified as low quality. Furthermore, the certainty of evidence, assessed using the GRADE approach, was rated as high for 23 (20.00%) effects and moderate for 48 (41.74%) effects. High-certainty evidence supports specific DHI benefits, not a uniform effect across the cancer continuum. Effects depend on outcome, format, and care stage; future research should prioritize implementation science.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: